AVR 1.64% $18.00 anteris technologies ltd

Bio-Implants

  1. 7,961 Posts.
    lightbulb Created with Sketch. 502
    This is how the page reads now. Looks to have been updated not long ago. Could it be a hint as to the new product?

    Tissue bio-implants developed using the ADAPT® tissue engineering process more closely mimic the characteristics of normal human tissue. This promotes a more tolerant immune response with improved tissue ingrowth. Tissue exposed to the ADAPT® process has been shown to have significantly improved functionality and longer term durability of the resulting bio-implant.
    With the potential for a product lifespan free from calcification, clinicians may be able to intervene across a broader age spectrum and provide their patients with a solution for life.
    CardioCel®, a cardiovascular scaffold, is the first of a suite of implantable tissues generated by ADAPT® that offer medical professionals a potential improvement over the products they currently use. CardioCel® has regulatory approval and is being used by surgeons in centres across Europe and the US. The product also recently gained licence approval in Canada, special access approval in Singapore and is available under the Authorised Prescriber Scheme in Australia.
    Our technology also has applications in general and gynaecological surgery.
    Click here for more information on the science behind ADAPT®
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
(20min delay)
Last
$18.00
Change
-0.300(1.64%)
Mkt cap ! $346.0M
Open High Low Value Volume
$18.29 $18.30 $17.65 $181.7K 10.18K

Buyers (Bids)

No. Vol. Price($)
1 30 $17.72
 

Sellers (Offers)

Price($) Vol. No.
$18.00 499 1
View Market Depth
Last trade - 16.10pm 05/07/2024 (20 minute delay) ?
AVR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.